ProMIS Neurosciences (PMN) Common Equity (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Common Equity came in at $60.7 million in Q1 2026, up 541.04% YoY from $9.5 million in Q1 2025, and up 4924.25% on a QoQ basis from -$1.3 million in Q4 2025.
ProMIS Neurosciences (PMN) Common Equity (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Common Equity data on file, last reported at $60.7 million in Q1 2026.
- Quarterly Common Equity rose 541.04% year-over-year to $60.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.7 million (up 541.04% YoY) and the FY2025 annual result came in at -$1.3 million, down 107.63% from the prior year.
- Common Equity advanced to $60.7 million in Q1 2026, from -$1.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $60.7 million in Q1 2026 to a low of -$8.5 million in Q2 2023.
- A 5-year average of $6.2 million and a median of $3.7 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity plunged 265.31% — and 2025, when it jumped 12185.15%.
- Tracing PMN's Common Equity over 5 years: stood at -$1.3 million in 2022, then surged by 378.48% to $3.8 million in 2023, then jumped by 339.3% to $16.5 million in 2024, then plunged by 107.63% to -$1.3 million in 2025, then surged by 4924.25% to $60.7 million in 2026.
- The last three Common Equity figures came in at $60.7 million (Q1 2026), -$1.3 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | 49.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.40 Mn |
| Mar 31, 2026 | 60.72 Mn |
| Dec 31, 2025 | -1.26 Mn |
| Sep 30, 2025 | 9.19 Mn |
| Jun 30, 2025 | -382,579.00 |
| Mar 31, 2025 | 9.47 Mn |
| Dec 31, 2024 | 16.49 Mn |
| Sep 30, 2024 | 7.27 Mn |
| Jun 30, 2024 | -2.28 Mn |
| Mar 31, 2024 | 77,099.00 |
| Dec 31, 2023 | 3.75 Mn |
| Sep 30, 2023 | 6.75 Mn |
| Jun 30, 2023 | -8.53 Mn |
| Mar 31, 2023 | -6.18 Mn |
| Dec 31, 2022 | -1.35 Mn |
| Sep 30, 2022 | 729,764.00 |
| Jun 30, 2022 | 6.71 Mn |
| Mar 31, 2022 | 3.74 Mn |
| Dec 31, 2021 | 5.66 Mn |
| Sep 30, 2021 | 7.82 Mn |